Physician profile
Mark A Mcdaniel
NPI 1518997014
$6,715.60
in general payments reported to CMS, 2019-2025
38 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $1,276 · 2021: $1,165 · 2022: $389 · 2023: $670 · 2024: $1,121 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,234.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,219.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $989.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $685.92 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $563.79 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $347.22 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $325.26 | 2021-2025 | |
| Shield Therapeutics INC | $294.12 | 2023-2025 | Accrufer |
| Amarin Pharma, INC. | $286.19 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $173.15 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $172.19 | 2019-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.65 | 2021-2024 | Xifaxan, Trulance |
| Pfizer INC. | $141.88 | 2019-2021 | |
| Exact Sciences Corporation | $141.61 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Daiichi Sankyo INC. | $129.87 | 2019-2024 | Injectafer |
| Astellas Pharma US INC | $93.99 | 2019-2025 | Veozah |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.